NCT07127822View on ClinicalTrials.gov

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Gastric / Gastroesophageal Junction AdenocarcinomaMSI-H Cancer
Interventions
DRUG

Iparomlimab and Tuvonralimab

Iparomlimab and tuvonralimab for experimental arm

DRUG

First line chemotherapy plus PD-1/PD-L1 antibody

standard first-line chemotherapy（FOLFOX/XELOX/SOX）combined with PD-1/PD-L1 antibody for control arm

Trial Locations (1)

Unknown

Department of GI Oncology, Peking University Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Qilu Pharmaceutical Group Co., Ltd

UNKNOWN

lead

Peking University

OTHER